These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

207 related items for PubMed ID: 8206571

  • 1. Blood pressure-lowering effect of an orally active vasopressin V1 receptor antagonist in mineralocorticoid hypertension in the rat.
    Burrell LM, Phillips PA, Stephenson JM, Risvanis J, Rolls KA, Johnston CI.
    Hypertension; 1994 Jun; 23(6 Pt 1):737-43. PubMed ID: 8206571
    [Abstract] [Full Text] [Related]

  • 2. Effect of vasopressin antagonism on structure and mechanics of small arteries and vascular expression of endothelin-1 in deoxycorticosterone acetate salt hypertensive rats.
    Intengan HD, He G, Schiffrin EL.
    Hypertension; 1998 Oct; 32(4):770-7. PubMed ID: 9774378
    [Abstract] [Full Text] [Related]

  • 3. Effect of nonpeptide vasopressin receptor antagonists on developing, and established DOCA-salt hypertension in rats.
    Okada H, Suzuki H, Kanno Y, Saruta T.
    Clin Exp Hypertens; 1995 Apr; 17(3):469-83. PubMed ID: 7613523
    [Abstract] [Full Text] [Related]

  • 4. Central action of increased osmolality to support blood pressure in deoxycorticosterone acetate-salt rats.
    O'Donaughy TL, Qi Y, Brooks VL.
    Hypertension; 2006 Oct; 48(4):658-63. PubMed ID: 16966581
    [Abstract] [Full Text] [Related]

  • 5. Regulation of vasopressin receptors in deoxycorticosterone acetate-salt hypertension.
    Trinder D, Phillips PA, Risvanis J, Stephenson JM, Johnston CI.
    Hypertension; 1992 Oct; 20(4):569-74. PubMed ID: 1398892
    [Abstract] [Full Text] [Related]

  • 6. Effect of vasopressin V1- and V2-receptor stimulation on blood pressure in DOCA-salt hypertensive rats.
    Mimura Y, Ogura T, Yamauchi T, Otsuka F, Oishi T, Harada K, Hashimoto M, Ota Z.
    Acta Med Okayama; 1995 Aug; 49(4):187-94. PubMed ID: 7502678
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Effects of an orally active vasopressin V1 receptor antagonist.
    Burrell LM, Phillips PA, Stephenson J, Risvanis J, Hutchins AM, Johnston CI.
    Clin Exp Pharmacol Physiol; 1993 May; 20(5):388-91. PubMed ID: 8391950
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Effect of an intracerebroventricularly administered vasopressin V1 antagonist on blood pressure and heart rate in deoxycorticosterone-salt hypertensive rats.
    Toba K, Ouchi Y, Liang J, Akishita M, Orimo H.
    J Auton Nerv Syst; 1994 Dec 15; 50(2):123-9. PubMed ID: 7884152
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Reduced contractile sensitivity and vasopressin receptor affinity in DOCA-salt hypertension.
    Bockman CS, Jeffries WB, Pettinger WA, Abel PW.
    Am J Physiol; 1992 Jun 15; 262(6 Pt 2):H1752-8. PubMed ID: 1535757
    [Abstract] [Full Text] [Related]

  • 20. Effects of OPC-21268, an orally effective vasopressin V1 receptor antagonist in humans.
    Imaizumi T, Harada S, Hirooka Y, Masaki H, Momohara M, Takeshita A.
    Hypertension; 1992 Jul 15; 20(1):54-8. PubMed ID: 1319959
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.